Report on Management's transactions with ALK-Abello A/S B-shares and associated securities
September 12, 2014 at 05:55 am EDT
Share
COPENHAGEN, Denmark, Sept. 12, 2014 (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): Pursuant to section 28(a) of the Danish Securities Trading Act, ALK-Abello A/S shall report the following transactions based on the allotments of conditional shares which ALK has granted to the company's Board of Management in accordance with the incentive payments guidelines adopted at the company's annual general meeting on 12 March 2014:
Name
Jens Bager
Reason
President and CEO
Issuer
ALK-Abello A/S
ISIN code
DK0060027142
Type
Conditional shares
Transaction
Allotment
Allotment date
11 September 2014
Market
NASDAQ OMX Copenhagen A/S
Number
1,125
Market value
DKK 830,700
Name
Henrik Jacobi
Reason
Member of the Board of Management
Issuer
ALK-Abello A/S
ISIN code
DK0060027142
Type
Conditional shares
Transaction
Allotment
Allotment date
11 September 2014
Market
NASDAQ OMX Copenhagen A/S
Number
600
Market value
DKK 443,040
Name
Soeren Daniel Niegel
Reason
Member of the Board of Management
Issuer
ALK-Abello A/S
ISIN code
DK0060027142
Type
Condtional shares
Transaction
Allotment
Allotment date
11 September 2014
Market
NASDAQ OMX Copenhagen A/S
Number
600
Market value
DKK 443,040
Name
Flemming Pedersen
Reason
Member of the Board of Management
Issuer
ALK-Abello A/S
ISIN code
DK0060027142
Type
Conditional shares
Transaction
Allotment
Allotment date
11 September 2014
Market
NASDAQ OMX Copenhagen A/S
Number
600
Market value
DKK 443,040
ALK-Abello A/S
Contact: Steen Riisgaard, Chairman of the Board of Directors, tel. +45 4574 7576
ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Companyâs allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.
ALK-ABELLÓ A/S 
